Safety and tolerability of elubaquine (bulaquine, CDRI 80/53) for treatment of Plasmodium vivax malaria in Thailand |
Krudsood Srivicha
(Faculty of Tropical Medicine, Mahidol University)
Wilairatana Polrat (Faculty of Tropical Medicine, Mahidol University) Tangpukdee Noppadon (Faculty of Tropical Medicine, Mahidol University) Chalermrut Kobsiri (Faculty of Tropical Medicine, Mahidol University) Srivilairit Siripun (Faculty of Tropical Medicine, Mahidol University) Thanachartwet Vipa (Faculty of Tropical Medicine, Mahidol University) Muangnoicharoen Sant (Faculty of Tropical Medicine, Mahidol University) Luplertlop Natthanej (Faculty of Tropical Medicine, Mahidol University) Brittenham Gary M. (Department of Pediatrics and Medicine, Columbia University, College of Physicians and Surgeons) Looareesuwan Sornchai (Faculty of Tropical Medicine, Mahidol University) |
1 | Dutta GP, Puri SK, Bhaduri AP, Seth M (1989) Radical curative activity of a new 8-aminoquinoline derivative (CDRI 80/53) against Plasmodium cynomolgi B in monkeys. Am J Trop Med Hyg 41: 635-637 DOI |
2 | Looareesuwan S, Buchachart K, Wilairatana P, Chalermrut K, Rattanapong Y, Amradee S, Siripiphat S, Chullawichit S, Thimasan K, Ittiverakul M, Triampon A, Walsh DS (1997) Primaquine-tolerant vivax malaria in Thailand. Ann Trop Med Parasitol 91: 939-943 DOI ScienceOn |
3 | Mendis K, Sina BJ, Marchesini P, Carter R (2001) The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 64: 97-106 DOI |
4 | Srivastava P, Puri SK, Dutta GP, Pandey VC (1993) Effect of the anti-malarial agents primaquine and (N1-3-acetyl-4- 5-dihydro-2-furanyl)-N4-(6-methoxy-8-quinolinyl)1,4-pentanediamine on oxidative stress and anti-oxidant defences in mice. Biochem Pharmacol 46: 1859-1860 DOI ScienceOn |
5 | Anklesaria PS, Ashar VJ, Kshirsagar NA, Gupta KC (1994) Comparison of the effect of compound CDRI 80/53 [N1-(3 acetyl-4-5-dihydro-2 furanyl)-N4-(6-methoxy-8-quinolinyl)1,4-pentanediamine] with primaquine on human erythrocytes in vitro. In Tropical Diseases: Molecular Biology and Control Strategies, Kumar S, Sen AK, Dutta GP, Sharma RN (eds.). p 256-261, Publication and Information Directorate, Council of Scientific and Industrial Research, New Delhi, India |
6 | Bunnag D, Karbwang J, Thanavibul A, Chittamas S, Ratanapongse Y, Chalermrut K, Bangchang KN, Harinasuta T (1994) High dose of primaquine in primaquineresistant vivax malaria. Trans R Soc Trop Med Hyg 88: 218-219 DOI ScienceOn |
7 | Valecha N, Adak T, Bagga AK, Asthana OP, Srivastava JS, Joshi H, Sharma VP (2001) Comparative anti-relapse efficacy of CDRI compound 80/53 (bulaquine) vs primaquine in double blind clinical trial. Curr Sci 80: 561- 563 |
8 | Puri SK, Dutta GP (1990) Causal prophylactic activity of a new 8-aminoquinoline derivative against Plasmodium cynomolgi B in rhesus monkeys. Indian J Med Res 91: 197-199 |
9 | Looareesuwan S, Wilairatana P, Krudsood S, Treeprasertsuk S, Singhasivanon P, Bussaratid V, Chokjindachai W, Viriyavejakul P, Chalermrut K, Walsh DS, White J(1999) Chloroquine sensitivity of Plasmodium vivax in Thailand. Ann Trop Med Parasitol 93: 225-230 DOI |
10 | Puri SK, Srivastava R, Pandey VC, Sethi N, Dutta GP (1989) Methemoglobin toxicity and hematological studies on malaria anti-relapse compound CDRI 80/53 in dogs. Am J Trop Med Hyg 41: 638-642 DOI |
11 | Silachamroon U, Krudsood S, Treeprasertsuk S, Wilairatana P, Chalearmrult K, Mint HY, Maneekan P, White NJ, Gourdeuk VR, Brittenham GM, Looareesuwan S (2003) Clinical trial of oral artesunate with or without highdose primaquine for the treatment of vivax malaria in Thailand. Am J Trop Med Hyg 69: 14-18 |
12 | Baird JK, Leksana B, Masbar S, Fryauff DJ, Sutanihardja MA, Suradi, Wignall FS, Hoffman SL (1997) Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Am J Trop Med Hyg 56: 621-626 DOI |
13 | Wilairatana P, Silachamroon U, Krudsood S, Singhasivanon P, Treeprasertsuk S, Bussaratid V, Phumratanaprapin W, Srivilirit S, Looareesuwan S (1999) Efficacy of primaquine regimens for primaquine-resistant Plasmodium vivax malaria in Thailand. Am J Trop Med Hyg 61: 973-977 DOI |
14 | Chareonviriyaphap T, Bangs MJ, Ratanatham S (2000) Status of malaria in Thailand. Southeast Asian J Trop Med Public Health 31: 225-237 |
15 | Dutta GP, Puri SK, Pandey VC, Seth M, Bhaduri AP, Chatterjee SK, Asthana OP, Gupta KC (1994) New potential anti-malarials: anti-relapse compound CDRI 80/53. In Tropical Diseases: Molecular Biology and Control Strategies, Kumar S, Sen AK, Dutta GP, Sharma RN (eds.). p 276-285, Publication and Information Directorate, Council of Scientific and Industrial Research, New Delhi, India |
16 | Baird JK, Hoffman SL (2004) Primaquine therapy for malariamalaria. Clin Infect Dis 39: 1336-1345 DOI ScienceOn |
17 | Adak T, Valecha N, Sharma VP (2001) Plasmodium vivax polymorphism in a clinical drug trial. Clin Diagn Lab Immunol 8: 891-894 DOI ScienceOn |
18 | Baird JK (2004) Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother 48: 4075-4083 DOI ScienceOn |